Addex Therapeutics announces GABAB PAM candidate data

Addex Therapeutics (ADXN) announced preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator candidate in a bleomycin-induced idiopathic pulmonary fibrosis exacerbated chronic cough model. In studies evaluating chronic once-daily administration of a lead GABAB PAM candidate in BLM-exposed animals, robust and sustained antitussive efficacy was observed, with significant reductions in cough frequency and increased cough latency over the treatment period. Improved lung pathology outcomes, including lower Ashcroft scores and reduced percentage of affected lung tissue suggesting an impact on fibrosis, were demonstrated compared to untreated BLM-exposed animals at both Day 7 and Day 28. The safety profile remained favorable, with no meaningful changes in respiratory rate, or body temperature. The compound was well tolerated throughout the study, supporting its potential for chronic administration.